| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| WB Predicted band size | 14 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human B2M |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于B2M(β-2微球蛋白)抗体的研究文献摘要概览：
---
1. **文献名称**：*Targeting B2M in cancer immunotherapy: Mechanisms and therapeutic prospects*
**作者**：Li, X., et al.
**摘要**：探讨B2M在肿瘤免疫逃逸中的作用，发现B2M抗体可通过阻断其与MHC I类分子结合，恢复细胞毒性T细胞对肿瘤的识别，增强免疫检查点抑制剂疗效，为联合治疗提供理论依据。
2. **文献名称**：*Anti-B2M monoclonal antibody inhibits amyloid fibril formation in dialysis-related amyloidosis*
**作者**：Yamaguchi, K., et al.
**摘要**：研究B2M抗体在透析相关淀粉样变性中的应用，证明抗体能特异性结合游离B2M蛋白，抑制其聚集形成淀粉样纤维，为延缓疾病进展提供潜在治疗策略。
3. **文献名称**：*B2M as a biomarker for immune dysfunction and antibody-mediated rejection in organ transplantation*
**作者**：Smith, J.R., et al.
**摘要**：分析移植患者中B2M水平与抗体介导排斥反应(AMR)的关联，提出抗B2M抗体可能通过激活补体途径加剧排斥，提示监测B2M抗体水平有助于早期诊断和干预。
---
注：以上文献名为虚拟示例，实际研究中建议通过PubMed或Web of Science检索关键词“B2M antibody”、“Beta-2 Microglobulin therapeutic”获取具体文献。
**Background of B2M Antibodies**
Beta-2 microglobulin (B2M), a 12-kDa protein, is a non-polymorphic subunit of the major histocompatibility complex (MHC) class I molecule, essential for antigen presentation to T-cells. It is ubiquitously expressed on nucleated cells and circulates in bodily fluids. B2M plays a critical role in maintaining MHC I structural stability and immune surveillance.
Elevated B2M levels are linked to pathological conditions. In chronic kidney disease, impaired renal clearance leads to serum B2M accumulation, contributing to dialysis-related amyloidosis. In cancers like multiple myeloma and lymphomas, B2M overexpression correlates with tumor burden, prognosis, and drug resistance, making it a biomarker for disease monitoring.
B2M antibodies are tools for detecting B2M in research and diagnostics. They are used in immunohistochemistry, ELISA, and flow cytometry to study MHC I expression, immune dysregulation, and B2M-related pathologies. Therapeutically, B2M-targeting antibodies are explored in cancer immunotherapy, aiming to disrupt MHC I-mediated immune evasion. Additionally, anti-B2M CAR-T cells and bispecific antibodies are under investigation for hematologic malignancies.
Recent studies also highlight B2M’s role in neurodegenerative diseases, such as Alzheimer’s, where its interaction with amyloid-β may influence pathology. This expands the potential applications of B2M antibodies in both neurological research and therapeutic development.
Overall, B2M antibodies are pivotal in understanding immune regulation, disease mechanisms, and advancing targeted therapies.
×
